MilliporeSigma granted foundational CRISPR-Cas9 U.S. patents
MilliporeSigma announced on May 11 that two of its CRISPR-Cas9-assisted genome-editing patents have been allowed in the U.S. The allowances cover cleavage and integration technology, which enables the research of knock-in/out mutations for the creation of disease models and development of gene therapies. Read More
ABL Europe to manufacture Themis SARS-CoV-2 vaccine in France
Biopharmaceutical company Themis and contract development and manufacturing organization ABL Europe announced that they have signed an agreement to manufacture a SARS-CoV-2 vaccine candidate in preparation for clinical trials. Read More
Sorrento, Mount Sinai to develop targeted SARS-CoV-2 antibody treatment
Sorrento Therapeutics and Mount Sinai Health System have joined forces to develop an antibody therapy called COVI-Shield to treat COVID-19. Read More
Bio-Rad posts increased Q1 revenue during pandemic
For the quarter revenue increased to $571.6 million, compared with $554 million in the first quarter of 2019. Meanwhile, net income in the first quarter plummeted to $685.9 million from approximately $865 million in the same quarter a year ago. Read More
Gladstone opens institutes to study unsolved diseases
Gladstone Institutes plans to launch two new biomedical research institutes in San Francisco to broaden its impact on unsolved diseases, including COVID-19. Read More
PerkinElmer Q1 revenues edge up, profit edges down
In financial results for the first quarter, PerkinElmer saw revenues grow slightly, but net income slipped. Read More
Danaher announces chief executive transition
Danaher announced on May 6 that Executive Vice President Rainer Blair will succeed Thomas Joyce Jr. as president and CEO when Joyce retires on September 1. Read More
Caribou, MaxCyte enter CRISPR license agreement
Caribou Biosciences and MaxCyte have announced a clinical and commercial license agreement for the development of Carbiou's CAR-T cell therapy program. Read More
Thermo Fisher launches SARS-CoV-2 GlobalAccess Sequencing Program
Thermo Fisher Scientific is providing 50 units of its Ion Torrent Genexus system at a subsidized price to support global COVID-19 research as part of its SARS-CoV-2 GlobalAccess Sequencing Program. Read More
Certara, DMTC study preventative use of chloroquine for COVID-19
Certara and DMTC have entered into a research collaboration to evaluate the preventative use of chloroquine in healthcare workers at risk of infection from SARS-CoV-2, the coronavirus strain responsible for COVID-19. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter